Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis

Li-Ting Lai¹, Wei-Guo Gu¹, Ming-Bin Hu¹, Wei-Jia Wang², Shan-Shan Wang², Ya-Jun Huai³, Jin-Hong Mei²*, Chun-Liang Wang³*  

¹Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China  
²Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China  
³Department of Neurosurgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China  
*Equal contribution

Correspondence to: Jin-Hong Mei, Chun-Liang Wang; email: mjhdctor@126.com, https://orcid.org/0000-0002-7082-3139; wclac0249@126.com, https://orcid.org/0000-0003-0958-6207

Keywords: immunotherapy, cancer, therapeutic efficacy, sex-specific differences, meta-analysis

Received: January 11, 2021  Accepted: May 14, 2021  Published: June 4, 2021

Copyright: © 2021 Lai et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Although disease susceptibility is known to differ between men and women, it is controversial whether the efficacy of immune checkpoint inhibitors for malignancies also differs between the sexes. We conducted a meta-analysis to explore the impact of sex on immune checkpoint inhibitor treatment outcomes. We searched PubMed, Embase and the Cochrane Library databases from inception to October 1, 2020 for randomized controlled trials of immune checkpoint inhibitors with hazard ratios (HRs) stratified by sex. We calculated the pooled HRs for men and women using the ln(HR), and assessed the heterogeneity between the two estimates through an interaction test. In total, 22,268 patients from 39 randomized controlled trials were included. Immune checkpoint inhibitors yielded better overall survival than conventional agents in both men (HR: 0.75, 95% confidence interval [CI]: 0.71–0.80) and women (HR: 0.77, 95% CI: 0.70–0.85). Progression-free survival benefits were also observed in both men (HR: 0.64, 95% CI: 0.58–0.70) and women (HR: 0.67, 95% CI: 0.58–0.77) treated with immune checkpoint inhibitors. No sex differences in the response to immune checkpoint inhibitors were found when overall survival and progression-free survival were used as the endpoints.

INTRODUCTION

Polymorphisms and other variations in genes encoding immune proteins may cause sex differences in immunity [1] and immune-related disease susceptibility [2, 3], whether the genes are expressed on sex chromosomes or autosomes. In insects, birds, mammals and other species, males tend to have lower innate and adaptive immune responses than females, and thus differ in their exposure to, recognition of, removal of and spread of pathogenic microorganisms. In general, women produce higher levels of basal immunoglobulin and antibodies against pathogens and vaccines than men. Further, CD3+ and CD4+ T cell counts, CD4+ to CD8+ T cell ratios and Th1 responses are higher in women than in men [1, 4, 5].

Men generally are at higher risk for malignancies than women. Moreover, the cancer-related mortality rate is almost two times higher in men than in women, with sex differences being most significant in laryngeal, esophageal, bladder and lung cancers [6, 7]. On the other hand, women account for 80% of all autoimmune disease cases worldwide, including Sjogren’s syndrome, systemic lupus erythematosus, scleroderma, thyroid disease and myasthenia gravis [8]. These sex differences reflect the effects of hormones, genes and the environment on the immune system, which can change throughout a person’s life [1, 9].

Imunosuppression and the escape of malignant tumor cells are key events in carcinogenesis [10]. These
processes are controlled by immune checkpoints (a series of co-stimulatory and co-inhibitory receptors and their ligands), among which the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathways are significant therapeutic targets. These pathways are important for immune homeostasis under physiological conditions, but also can be mechanisms whereby carcinoma cells escape immune surveillance. Monoclonal antibodies have been developed against PD-1/PD-L1 (e.g., pembrolizumab, nivolumab, tezolizumab, a durvalumab) and CTLA-4 (e.g., ipilimumab and tremelimumab), and their clinical application has launched a new era of cancer treatment [11, 12].

Sex hormones regulate the PD-1/PD-L1 signaling pathway, and may influence immune function by enhancing the PD-1 co-stimulatory pathway [13]. In animal models, sex differences have been observed in tumor immunity and immunotherapy responses [14]. However, an in vivo study on cytotoxic T cell-suppressing agents revealed no differences in their inhibition of either immunity or lymphocyte proliferation between men and women [15]. In a study evaluating prednisolone kinetics and responses, women exhibited a lower clearance, higher systemic exposure and higher distribution volume than men after a single oral dose; nevertheless, these pharmacokinetic changes did not lead to sex differences in the overall response to prednisolone [16].

Few studies have evaluated pharmacodynamics based on sex, especially for oncology agents. A meta-analysis by Conforti et al. [17] indicated that male patients benefited more from immunotherapy than female patients; however, another analysis found that the effects of anti-PD-1 and anti-CTLA-4 treatments in advanced cancer patients did not differ significantly between the sexes [18]. Thus, it remains to be clarified whether there are sex-related differences in the therapeutic benefits of cancer treatments.

In this systematic review and meta-analysis, we explored the impact of sex on immune checkpoint inhibitor treatment outcomes in cancer patients. We hypothesized that the efficacy of immune checkpoint inhibitors would not depend on sex.

**RESULTS**

**Study selection**

Our initial search strategy identified 14,213 articles. After screening the articles based on their titles and abstracts, we excluded 13,865 studies that did not conform to the inclusion criteria. Then, we carefully scanned through the full texts of the remaining 348 articles, and selected 39 studies [19–57] for the final analysis. Among these, 33 studies [19–46, 53–57] provided overall survival (OS) data for men and women, and were used in the qualitative analysis of OS. In addition, 20 of the studies [21, 22, 27, 35–39, 42, 45, 47–56] reported data on progression-free survival (PFS) by sex, and were used for the qualitative analysis of PFS. Supplementary Figure 1 displays the research selection flowchart.

**Characteristics of the included studies**

The 39 randomized controlled trials included in this study involved a total of 22,268 advanced cancer patients, of whom 15,314 (69%) were male and 6,954 (31%) were female. The main characteristics of the included studies are shown in Table 1. All the studies were multicenter randomized controlled trials published between 2010 and 2020. The number of subjects per study ranged from 120 to 1,274. There were 34 phase III trials, four phase II trials and one phase II/III trial (Table 1).

Seventeen studies were carried out in non-small cell lung cancer (NSCLC) patients; nine in melanoma patients; two each in gastric or gastro-esophageal junction carcinoma, head and neck squamous cell cancer, small cell lung cancer, esophageal squamous cell carcinoma and renal cell carcinoma patients; and one each in mesothelioma, hepatocellular carcinoma and urothelial carcinoma patients. Among the 22,268 subjects, 4,113 (14%) were melanoma patients and 10,954 (36%) were NSCLC patients. All the studies were performed in metastatic settings. No trial using PD-1/PD-L1 or CTLA-4 monoclonal antibodies as an intervention in patients with early malignant tumors reported the HRs for mortality outcomes by sex. Participants in the intervention group received pembrolizumab in 12 studies, nivolumab in 10 studies, atezolizumab in 6 studies, tremelimumab in 2 studies, avelumab in 2 studies, camrelizumab in 1 study and durvalumab in 1 study.

The primary endpoint for all eligible studies was PFS or OS (reviewed by an independent center for blinding). Random sequences were generated in all trials. The included studies were found to have moderate to good methodological quality (Supplementary Figure 2, Supplementary Figure 3). The main problem affecting the quality of the research was lack of blinding, as some of the studies were open-labeled (no blinding of participants and personnel) rather than double-blinded [31, 37].

**OS analysis**

The analysis of OS included 19,332 patients, of whom 13,359 (69%) were male and 5,973 (31%) were female.
| Study                  | Phase | Tumour type                        | Treatment groups                                                                 | Patients | Number of men (%) | Number of women (%) |
|-----------------------|-------|------------------------------------|----------------------------------------------------------------------------------|----------|-------------------|---------------------|
| Hodi et al. (2010)    | 3     | Melanoma                           | Ipilimumab plus gp100 vs gp100; ipilimumab vs gp100                              | 676      | 401 (59%)         | 275 (41%)           |
| Robert et al. (2011)  | 3     | Melanoma                           | Ipilimumab plus dacarbazine vs dacarbazine plus placebo                           | 502      | 301 (60%)         | 201 (40%)           |
| Robert et al. (2015)  | 3     | Melanoma                           | Pembrolizumab every 2 weeks vs ipilimuman; pembrolizumab every 3 weeks vs ipilimuman | 834      | 497 (60%)         | 337 (40%)           |
| Hodi et al. (2016)    | 2     | Melanoma                           | Ipilimumab plus nivolumab vs ipilimuman plus placebo                             | 142      | 95 (67%)          | 47 (33%)            |
| Robert et al. (2015)  | 3     | Melanoma                           | Nivolumab vs dacarbazine                                                         | 418      | 246 (59%)         | 172 (41%)           |
| Larkin et al. (2018)  | 3     | Melanoma                           | Nivolumab vs chemotherapy                                                         | 405      | 261 (64%)         | 144 (36%)           |
| Ribas et al. (2013)   | 3     | Melanoma                           | Tremelimumab vs chemotherapy                                                     | 655      | 372 (57%)         | 283 (43%)           |
| Reck et al. (2016)    | 3     | Small-cell lung cancer             | Ipilimumab plus etoposide plus platinum vs placebo                               | 954      | 643 (67%)         | 311 (33%)           |
| Carbone et al. (2017) | 3     | NSCLC                              | Nivolumab vs chemotherapy                                                         | 541      | 332 (61%)         | 209 (39%)           |
| Reck et al. (2016)    | 3     | NSCLC                              | Pembrolizumab vs chemotherapy                                                     | 305      | 187 (61%)         | 118 (39%)           |
| Herbst et al. (2016)  | 2/3   | NSCLC                              | Pembrolizumab (2 mg/kg) vs pembrolizumab (10 mg/kg) vs docetaxel                  | 1033     | 634 (61%)         | 399 (39%)           |
| Brahmer et al. (2015) | 3     | NSCLC                              | Nivolumab vs docetaxel                                                            | 272      | 208 (76%)         | 64 (24%)            |
| Govindan et al. (2017)| 3     | NSCLC                              | Ipilimumab plus chemotherapy vs chemotherapy                                       | 749      | 635 (85%)         | 114 (15%)           |
| Borghaei et al. (2015)| 3     | NSCLC                              | Nivolumab vs docetaxel                                                            | 582      | 319 (55%)         | 263 (45%)           |
| Maio et al. (2017)    | 2b    | Mesothelioma                       | Tremelimumab vs placebo                                                           | 571      | 434 (76%)         | 137 (24%)           |
| Motzer et al. (2015)  | 3     | Renal cell carcinoma               | Nivolumab vs everolimus                                                          | 821      | 619 (75%)         | 202 (25%)           |
| Bellmunt et al. (2017)| 3     | Urothelial carcinoma               | Pembrolizumab vs chemotherapy                                                     | 542      | 402 (74%)         | 140 (26%)           |
| Ferris et al. (2016)  | 3     | Head and neck squamous-cell carcinoma| Nivolumab vs chemotherapy                                                          | 361      | 300 (83%)         | 61 (17%)            |
| Cohen et al. (2018)   | 3     | Head and neck squamous-cell carcinoma| Pembrolizumab vs chemotherapy                                                      | 495      | 412 (83%)         | 83 (17%)            |
| Kang et al. (2017)    | 3     | Gastric or gastro-oesophageal junction cancer | Nivolumab vs placebo                                                                | 493      | 348 (71%)         | 145 (29%)           |
| Paz-Ares et al. (2018)| 3     | NSCLC                              | Pembrolizumab puls chemotherapy vs chemotherapy                                   | 559      | 455 (81%)         | 104 (19%)           |
| Gandhi et al. (2018)  | 3     | NSCLC                              | Pembrolizumab puls chemotherapy vs chemotherapy                                   | 616      | 363 (59%)         | 253 (41%)           |
| West et al. (2019)    | 3     | NSCLC                              | Atezolizumab puls chemotherapy vs chemotherapy                                     | 679      | 400 (59%)         | 279 (41%)           |
| Antonia et al. (2018) | 3     | NSCLC                              | Chemoradiotherapy plus durvalumab vs Chemoradiotherapy                              | 713      | 500 (70%)         | 213 (30%)           |
| Horn et al. (2018)    | 3     | Small-cell lung cancer             | Atezolizumab puls chemotherapy vs chemotherapy                                     | 403      | 261 (65%)         | 142 (35%)           |
| Mok et al. (2019)     | 3     | NSCLC                              | Pembrolizumab vs chemotherapy                                                     | 1274     | 902 (71%)         | 372 (29%)           |
| Rittmeyer et al. (2017)| 3    | NSCLC                              | Atezolizumab vs docetaxel                                                         | 850      | 520 (61%)         | 330 (39%)           |
| Barlesi et al. (2018) | 3     | NSCLC                              | Avelumab vs chemotherapy                                                           | 529      | 367 (69%)         | 162 (31%)           |
| Jotte et al. (2020)   | 3     | NSCLC                              | Atezolizumab puls chemotherapy vs chemotherapy                                     | 683      | 557 (82%)         | 126 (18%)           |
| Kato et al. (2019)    | 3     | Oesophageal squamous cell carcinoma| Nivolumab vs chemotherapy                                                          | 419      | 364 (87%)         | 55 (13%)            |
| Shitara et al. (2018) | 3     | Gastric or gastro-oesophageal junction cancer | Pembrolizumab vs paclitaxel                                                       | 395      | 286 (72%)         | 109 (28%)           |
| Finn et al. (2019)    | 3     | Hepatocellular carcinoma           | Pembrolizumab vs placebo                                                           | 413      | 338 (82%)         | 75 (18%)            |
| Huang et al. (2020)   | 3     | Oesophageal squamous cell carcinoma| Pembrolizumab vs placebo                                                           | 448      | 400 (89%)         | 48 (11%)            |
| Papadimitrak-opoulou et al. (2018)| 3     | NSCLC                              | Atezolizumab puls chemotherapy vs chemotherapy                                     | 578      | 384 (66%)         | 194 (34%)           |
| Ribas et al. (2015)   | 2     | Melanoma                           | Pembrolizumab (2 mg/kg) vs pembrolizumab (10 mg/kg) vs chemotherapy                | 361      | 213 (59%)         | 148 (41%)           |
| Hellmann et al. (2018)| 3     | NSCLC                              | Nivolumab vs ipilimumab                                                           | 299      | 204 (68%)         | 95 (32%)            |
| Motzer et al. (2019)  | 3     | Renal cell carcinoma               | Avelumab plus axitinib vs sunitinib                                               | 886      | 660 (74%)         | 226 (26%)           |
| Ascierto et al. (2019)| 2     | Melanoma                           | Pembrolizumab plus dabrafenib plus trametinib vs placebo plus dabrafenib plus trametinib | 120      | 69 (58%)          | 51 (42%)            |
| Socinski et al. (2018)| 3     | NSCLC                              | Atezolizumab puls chemotherapy vs chemotherapy plus bevacizumab                   | 692      | 425 (61%)         | 267 (39%)           |

Abbreviation: NSCLC: non–small-cell lung cancer.

Men treated with immune checkpoint inhibitor monotherapy or combination therapy had a significantly lower risk of mortality than men who received chemotherapy, anti-angiogenesis therapy or other treatments (OS HR: 0.75, 95% CI: 0.71–0.80, P < 0.001; Figure 1). In women, the benefit of immune
checkpoint inhibitor treatment compared with the control treatment was smaller (OS HR: 0.77, 95% CI: 0.70–0.85; Figure 2). A random model was applied due to substantial heterogeneity among the single-study estimates in men ($I^2 = 46.5\%, P = 0.002$) and women ($I^2 = 47.0\%, P = 0.001$). The pooled interaction of the OS HR between male and female patients was 0.76 (95% CI: 0.72–0.79, $P < 0.001$).

**PFS analysis**

The analysis of PFS included 10,711 patients, of whom 7,101 (66%) were male and 3,610 (34%) were female. Men treated with immune checkpoint inhibitor monotherapy or combination therapy had a significantly lower risk of mortality than men who received chemotherapy, anti-angiogenesis therapy or other treatments (PFS HR: 0.64, 95% CI: 0.58–0.70; Figure 3). In women, the survival benefit of PD-1/PD-L1 or CTLA-4 inhibitor treatment compared with the control treatment was smaller (PFS HR: 0.67, 95% CI: 0.58–0.77; Figure 4). The pooled interaction of the PFS HR between male and female patients was 0.65 (95% CI: 0.60–0.70, $P < 0.001$). There were no significant differences in the treatment effects of immune checkpoint inhibitors between the sexes, despite the lower pooled HRs for OS and PFS in men ($P = 0.91$ and $P = 0.80$, respectively).

**Subgroup analysis**

Figures 5 and 6 display the results of our subgroup analysis. The subgroup analysis of OS was based on the cancer histological type and the intervention agent.
target. The subgroup analysis of PFS was only based on the cancer histological type, because 19 of the trials used PD-1 inhibitors, while only one trial used a combination of PD-1 and CTLA-4 inhibitors. Among patients with melanoma, immune checkpoint inhibitors had greater efficacy (i.e., lower pooled HRs) in men than in women. However, the heterogeneity test of the sex-related interactions among the subgroups was not statistically significant.

**Publication bias and sensitivity analyses**

To assess potential publication bias, we used the Begg and Egger tests. In the Egger test, the P-values for OS and PFS were 0.712 and 0.256, respectively. In the Begg test, the P-values for OS and PFS were 0.054 and 0.154, respectively, indicating that there was no publication bias (Supplementary Figures 4–7). To reduce the impact of a single trial on the overall study, we also performed a sensitivity analysis, which suggested that the results of the meta-analysis were robust and reliable (Supplementary Figures 8 and 9).

**DISCUSSION**

It has been unclear whether there are sex-related differences in the therapeutic benefits of PD-1/PD-L1 or CTLA-4 inhibitors for cancer treatment. In the current study, we found that the efficacy of immune checkpoint inhibitors compared with control treatments did not differ significantly between men and women. Consistent findings were obtained in subgroup analyses by cancer type and intervention agent target.

![Figure 2. Overall survival hazard ratio in female patients in the immune checkpoint inhibitor group compared with the control group.](image-url)
Our findings contrasted with those of a previous meta-analysis [17] in which immune checkpoint inhibitors had greater survival benefits for men than for women. Our results also differed from those of a recent study [58] that suggested that influenza vaccines had greater benefits in women than in men, while tumor necrosis factor therapy for rheumatoid arthritis and immune checkpoint inhibitor therapy for tumors had greater therapeutic efficacy in men than in women. These inconsistencies may reflect differences in statistical power and study endpoints. A small sample size, low statistical power and prejudice against the null hypothesis may reduce the probability of determining the true effect and diminish the likelihood that statistically significant results reflect true effects [59, 60].

One advantage of the current analysis was the quality of the available research. Most of the data were from phase III randomized controlled trials. The OS analysis included 19,332 subjects, and the PFS analysis included 10,711 subjects. Our search date was more recent than that of the previous meta-analysis, leading to the addition of 13 large-scale clinical trials. This increased the number of patients by 7,981, including 5,713 (72%) men and 2,268 (28%) women.

In addition, we were able to extend the scope of the study by adding trials on immunotherapy agents such as atezolizumab, durvalumab, avelumab and camrelizumab, which were not included in the previous analysis. Mok et al. [40] compared the survival benefits of pembrolizumab (n = 637) and the investigator’s choice of chemotherapy (n = 637) as first-line treatments in previously untreated advanced NSCLC patients (KEYNOTE-042). This phase III, open-label clinical trial included 1,274 subjects (902 men and 372 women), was carried out at 213 medical institutions worldwide, lasted over three years (actual study start date: October 30, 2014; actual primary completion date: February 26, 2018), and accordingly contributed significantly to the pooled HR. The PACIFIC trial [38] compared

---

Figure 3. Progression-free survival hazard ratio in male patients in the immune checkpoint inhibitor group compared with the control group.
durvalumab ($n = 476$) with placebo treatment ($n = 237$) after chemoradiotherapy in 713 stage III NSCLC patients (500 men and 213 women), and demonstrated that the OS benefit from immune checkpoint inhibitor treatment was greater in female patients (HR: 0.46, 95% CI: 0.30–0.73) than in male patients (HR: 0.78, 95% CI: 0.59–1.03). Huang et al. [46] compared camrelizumab ($n = 228$) with chemotherapy ($n = 220$) as the second-line treatment for advanced/metastatic esophageal cancer in the ESCORT study. The trial involved 400 male and 48 female patients, and revealed a stronger OS benefit in female patients (HR: 0.45, 95% CI: 0.21–0.93) than in male patients (HR: 0.75, 95% CI: 0.60–0.93).

Another strength of our study was the addition of PFS as a study endpoint, which reinforced our conclusions. The PFS analysis included 10,711 participants from 20 trials. The KEYNOTE 189 trial [36] investigated platinum-based chemotherapy plus either pembrolizumab ($n = 410$) or placebo treatment ($n = 206$) in 616 NSCLC patients (363 men and 253 women), and detected a greater PFS benefit in women (HR: 0.40, 95% CI: 0.29–0.54) than in men (HR: 0.66, 95% CI: 0.50–0.87). Similar findings were obtained from the IMpower133 study [39], in which a remarkably greater therapeutic effect was observed in women (HR: 0.59, 95% CI: 0.41–0.85) than in men (HR: 0.87, 95% CI: 0.67–1.13). Clinical trials such as IMpower150, JAVELIN Renal 101 and KEYNOTE-022 [47, 50, 51] used PFS as the research endpoint, but reported no data on OS stratified by sex; thus, the analysis of these studies was essential for detecting the true effect.

Sex-related differences are often reflected in pharmacokinetic differences, but pharmacokinetic differences do not necessarily lead to pharmacodynamic differences. For instance, aspirin tends to be absorbed more quickly by women than by men after oral administration, but its bioavailability does not differ between the sexes [61]. In addition, women have a higher methylprednisolone clearance rate than men, but they are also more
sensitive to the drug and have a significantly smaller 50% inhibitory concentration for the inhibition of cortisol secretion, so their net response is similar [62].

Women generally have lower body weights, higher body fat contents and lower muscle contents than men, which may alter organ blood flow and function, thus influencing the pharmacokinetics of many agents [63]. Nevertheless, body weight is directly proportional to the glomerular filtration rate, and men are usually larger than women, so differences in renal excretion rates may well reflect differences in body weight. The renal clearance of fluoroquinolone drugs such as fleroxacin was found to be significantly higher in men than in women, but not after adjustment for weight [64]. Clinical oncology medications (including immune checkpoint inhibitors) are often standardized by body weight or body surface area, which may adjust the pharmacokinetic parameters and offset the differences in pharmacodynamics between men and women.

One limitation of our study was the use of published findings from trials rather than data from individual patients. This prevented us from researching the effects of PD-1 or CTLA-4 inhibitors according to factors such as region, nutritional status or menopausal status. Given their important effects on the immune system, these environmental and hormonal factors are worth investigating [65–68]. In addition, we tested subgroups (male and female patients) in the eligible trials, which may have introduced bias into our results, although the control and intervention arms were balanced in most of the studies. Finally, the differences in OS and PFS

![Figure 5. Subgroup analyses of overall survival in patients assigned to the intervention and control groups.](image-url)
between the sexes may have been due to other factors such as comorbidities, age and reproductive status, which were not considered in the trials. Despite these limitations, we believe that our research is valuable, as we systematically assessed data on all the approved immune checkpoint inhibitors and 22,268 patients. To the best of our knowledge, this is the largest meta-analysis of sex differences in immunotherapy responses.

In conclusion, in this up-to-date meta-analysis of all the available studies on immunotherapy in advanced or metastasized cancer, there were no sex differences in the efficacy of PD-1/PD-L1 or CTLA-4 inhibitors. We found no evidence that patient sex should be considered when deciding on the appropriateness of administering immune checkpoint inhibitors to patients with advanced cancers.

**MATERIALS AND METHODS**

**Literature search and selection criteria**

This study followed the recommendations of the Cochrane Manual for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [69]. The registration number was INPLASY202120071.

We comprehensively searched for phase II and III randomized controlled trials in the PubMed, Embase and Cochrane Library databases from their inception to October 1, 2020. We examined publications from the two major conferences, namely, the European Society of Medical Oncology and the American Society of Clinical Oncology. The keywords were immune checkpoint inhibitors, PD-1, programmed death receptor 1, CTLA-4, cytotoxic T-lymphocyte-associated protein 4, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab and tremelimumab (see Supplementary Materials for details).

The eligibility criteria for inclusion were as follows. First, the clinical trials had to evaluate PD-1/PD-L1 inhibitors, CTLA-4 inhibitors or a combination thereof in advanced carcinoma patients, with the primary outcome measure being the HR for OS or PFS.
according to the patient’s sex. Second, the trials had to compare immunotherapies with other therapies such as the investigator’s choice of chemotherapy or placebo.

We excluded retrospective studies, prospective observational cohort studies and single-arm phase I and phase II trials (i.e., non-randomized controlled trials). Review articles, case reports, guidelines, conference abstracts, meta-analyses, quality-of-life studies, basic science papers and editorials were also excluded. When a trial was reported in multiple articles or mixed citations, we chose the one with the latest and most complete data. All discrepancies were resolved through discussion. All the randomized controlled trials included in this study represented unique research.

Risk of bias assessment

The risk of bias was assessed using the Cochrane Collaboration tool [70], which evaluates seven factors: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other sources of bias. We examined each study and marked the risk of bias as high, low or unclear. Each low-risk aspect was assigned 1 point, so the highest possible total score was 7 points. Two authors independently evaluated the quality of each article. Differences were resolved through a discussion with all researchers.

Data analysis

The primary endpoint was the heterogeneity in the efficacy of PD-1/PD-L1 or CTLA-4 inhibitors between male and female patients, determined as the difference in the ln(HR) for OS and/or PFS. Accordingly, for each trial, we extracted the HRs and 95% CIs for OS and PFS separately for men and women. Cochrane’s Q statistic was used to assess the statistical heterogeneity among the different studies and subgroups. $I^2$ was computed to assess the degree of inconsistency in effect due to heterogeneity among studies. Heterogeneity was defined as high, moderate or low based on $I^2$ values of 75%, 50% and 25%, respectively. A $P$-value < 0.1 indicated greater heterogeneity [71].

The pooled HRs for death in male and female patients were calculated using random effects models. The difference in treatment efficacy between male and female patients was assessed through an interaction test and represented as $P$ for the interaction. Subgroup analyses based on the interventional drug target type and cancer type were performed to investigate the influence of sex on the efficacy of immune checkpoint inhibitors in various situations. We only considered subgroups that included more than two trials.

Potential publication bias was assessed using Begg and Egger tests and presented as a funnel plot [72, 73]. All analyses were conducted using Stata version 14.0 (StataCorp, College Station, TX, USA). All $P$-values were two-sided, and $P < 0.05$ was considered statistically significant.

Abbreviations

CTLA-4: cytotoxic T-lymphocyte-associated protein 4; PD-1: programmed cell death 1; PD-L1: programmed cell death 1 ligand 1; CI: confidence interval; HR: hazard ratio; NSCLC: non-small cell lung cancer; OS: overall survival; PFS: progression-free survival.

AUTHOR CONTRIBUTIONS

JH.M. and CL.W. designed the study. LT.L., WG.G., MB.H., WJ.W., SS.W. and YJ.H. collected and analyzed the data and prepared the manuscript. LT.L. edited the manuscript. All the authors approved the final manuscript.

ACKNOWLEDGMENTS

We thank all the participants and researchers involved in the included clinical trials for their contributions.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest related to this study.

FUNDING

This work was supported by the National Natural Science Foundation of China (No. 81760448) and the Science and Technology Project of Jiangxi Provincial Health Commission (No. 20203122).

REFERENCES

1. Libert C, Dejager L, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010; 10:594–604. https://doi.org/10.1038/nri2815 PMID:20651746

2. Case LK, Toussaint L, Moussawi M, Roberts B, Saligrama N, Brossay L, Huber SA, Teuscher C. Chromosome y regulates survival following murine coxsackievirus b3 infection. G3 (Bethesda). 2012; 2:115–21.
https://doi.org/10.1534/g3.111.001610
PMID: 2384388

3. vom Steeg LG, Klein SL. SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog. 2016;12:e1005374. https://doi.org/10.1371/journal.ppat.1005374 PMID: 26891052

4. Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danielli GA, Clementi M, Chieco-Bianchi L. Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med. 1995; 1:1279–83. https://doi.org/10.1038/nm1295-1279 PMID: 7489409

5. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010; 10:338–49. https://doi.org/10.1016/S1473-3099(10)70049-9 PMID: 20417416

6. Cook MB, Dawsey SM, Freedman ND, Inskip PD, Wichner SM, Quraishi SM, Devesa SS, McGlynn KA. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009; 18:1174–82. https://doi.org/10.1158/1055-9965.EPI-08-1118 PMID: 19293308

7. Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011; 20:1629–37. https://doi.org/10.1158/1055-9965.EPI-11-0246 PMID: 21750167

8. Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999; 283:1277–78. https://doi.org/10.1126/science.283.5406.1277 PMID: 10084932

9. Org E, Mehrabian M, Parks BW, Shipkova P, Liu X, Drake TA, Lusis AJ. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016; 7:313–22. https://doi.org/10.1080/19490976.2016.1203502 PMID: 27355107

10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230

11. Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018; 48:434–52. https://doi.org/10.1016/j.immuni.2018.03.014 PMID: 29562194

12. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359:1350–55. https://doi.org/10.1126/science.aar4060 PMID: 29567705

13. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, Bahar R, Kious MJ, Livi CB, Wall SR, Chen L, Zhang B, Shin T, Curiel TJ. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol. 2010; 185:2747–53. https://doi.org/10.1042/jimmunol.1000496 PMID: 20686128

14. Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res. 2006; 84:370–78. https://doi.org/10.1002/jnr.20881 PMID: 16676326

15. Ferron GM, Jusko WJ. Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J Pharmacol Exp Ther. 1998; 286:191–200. PMID: 9655860

16. Magee MH, Blum RA, Lates CD, Jusko WJ. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol. 2001; 41:1180–94. https://doi.org/10.1177/00912700012201273 PMID: 11697751

17. Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018; 19:737–46. https://doi.org/10.1016/S1470-2045(18)30261-4 PMID: 29778737

18. Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattiella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy? Oncotarget. 2017; 8:99336–46. https://doi.org/10.18632/oncotarget.22242 PMID: 29245905

19. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711–23. https://doi.org/10.1056/NEJMoa1003466 PMID: 20525992

20. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, et al. Ipilimumab
plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517–26.
https://doi.org/10.1056/NEJMoaa1104621
PMID: 21639810

21. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, et al, and KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372:2521–32.
https://doi.org/10.1056/NEJMoa1503093
PMID: 25891173

22. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016; 17:1558–68.
https://doi.org/10.1016/S1470-2045(16)30366-7
PMID: 27622997

23. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowsi P, McNeill C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebèe C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372:320–30.
https://doi.org/10.1056/NEJMoaa1412082
PMID: 25399552

24. Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018; 36:383–90.
https://doi.org/10.1200/JCO.2016.71.8023
PMID: 28671856

25. Ribas A, Kefferd R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31:616–22.
https://doi.org/10.1200/JCO.2012.44.6112
PMID: 23295794

26. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, et al. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016; 34:3740–48.
https://doi.org/10.1200/JCO.2016.67.6601
PMID: 27458307

27. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Culeanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, et al, and CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376:2415–26.
https://doi.org/10.1056/NEJMoaa1613493
PMID: 28636851

28. Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J, Vladimirov V, Fadeeva N, Lee KH, Kurata T, et al. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017; 35:3449–57.
https://doi.org/10.1200/JCO.2016.71.7629
PMID: 28854067

29. Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017; 18:1261–73.
https://doi.org/10.1016/S1470-2045(17)30446-1
PMID: 28729154

30. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Bosman JA, Procopio G, Pimack ER, Castellano D, Choueiri TK, Gurney H, et al, and CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373:1803–13.
https://doi.org/10.1056/NEJMoaa1501065
PMID: 26406148

31. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, et al, and KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376:1015–26.
https://doi.org/10.1056/NEJMoaa1613683
PMID: 28212060

32. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375:1856–67.
33. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, et al, and KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019; 393:156–67. https://doi.org/10.1016/S0140-6736(18)31999-8 PMID:30509740

34. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390:2461–71. https://doi.org/10.1016/S0140-6736(17)31827-5 PMID:28993052

35. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazieres J, Hermes B, Çay Şenler F, Csősz T, Fülop A, Rodríguez-Cid J, Wilson J, Sugawara S, et al, and KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379:2040–51. https://doi.org/10.1056/NEJMoa1810865 PMID:30280635

36. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, et al, and KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378:2078–92. https://doi.org/10.1056/NEJMoa1801005 PMID:29658856

37. West H, McLeod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reimnuth N, Sadiq A, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20:924–37. https://doi.org/10.1016/S1470-2045(19)30167-6 PMID:31122901

38. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaa M, Quantin X, et al, and PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379:2342–50. https://doi.org/10.1056/NEJMoa1809697 PMID:30280658

39. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Lam S, et al, and IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379:2220–29. https://doi.org/10.1056/NEJMoa1809064 PMID:30280641

40. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, et al, and KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393:1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7 PMID:30955977

41. Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018; 19:1468–79. https://doi.org/10.1016/S1470-2045(18)30673-9 PMID:30262187

42. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, Soo R, Conter HJ, Kozuki T, Huang KC, Graupner V, Sun SW, Hoang T, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020; 15:1351–60. https://doi.org/10.1016/j.jtho.2020.03.028 PMID:32302702

43. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20:1506–17. https://doi.org/10.1016/S1470-2045(19)30626-6 PMID:31582355

44. Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandała M, Ryu MH, Fornaro L, Olesiński T, Cagievic
C, Chung HC, Muro K, Goekkurt E, Mansoor W, et al, and KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392:123–33. https://doi.org/10.1016/S0140-6736(18)31257-1 PMID:29880231

45. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, You T, Garrido M, Chan SL, et al, and KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020; 38:193–202. https://doi.org/10.1200/JCO.19.01307 PMID:31790344

46. Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, et al, and ESCORT Study Group. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020; 21:832–42. https://doi.org/10.1016/S1470-2045(20)30110-8 PMID:32416073

47. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilio D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, et al, and IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378:2288–301. https://doi.org/10.1056/NEJMoai1716948 PMID:29863955

48. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O’Day SJ, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16:908–18. https://doi.org/10.1016/S1470-2045(15)00083-2 PMID:26115796

49. Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salmon P, Borghaei H, Ramalingam SS, Brahmer J, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378:2093–104. https://doi.org/10.1056/NEJMoai1801946 PMID:29658845

50. Motzer RJ, Penkov K, Haanen J, Rini B, Albiger L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, Lee JL, Vasiliev A, Miller WH Jr, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019; 380:1103–15. https://doi.org/10.1056/NEJMoa1816047 PMID:30779531

51. Ascierio PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019; 25:941–46. https://doi.org/10.1038/s41591-019-0448-9 PMID:31171878

52. Papadimitrakopoulou V, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G, Novello S, Orlandi F, Ball S, Goldschmidt J, Sanborn R, Hoang T, Mendus D, et al. OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. Journal of Thoracic Oncology. 2018; 13:S332–33.

53. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csösz T, Fülop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, et al, and KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375:1823–33. https://doi.org/10.1056/NEJMoai1606774 PMID:27718847

54. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387:1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7 PMID:26712084

55. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:123–35. https://doi.org/10.1056/NEJMoai1504627 PMID:26028407

56. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373:1627–39.
57. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, et al, and OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389:255–65. https://doi.org/10.1016/S0140-6736(16)32517-X PMID:27973833

58. Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biol Sex Differ. 2020; 11:24. https://doi.org/10.1186/s13293-020-00301-y PMID:32366281

59. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013; 14:365–76. https://doi.org/10.1038/nrn3475 PMID:23571845

60. Greenwald AG. Consequences of prejudice against the null hypothesis. Psychol Bull. 1975; 82:1–20.

61. Aarons L, Hopkins K, Rowland M, Brossel S, Thiercelin JF. Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. Pharm Res. 1989; 6:660–66. https://doi.org/10.1023/a:1015978104017 PMID:2510140

62. Lew KH, Ludwig EA, Milad MA, Donovan K, Middleton E Jr, Ferry JJ, Jusko WJ. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1993; 54:402–14. https://doi.org/10.1038/clpt.1993.167 PMID:8222483

63. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995; 50:222–39. https://doi.org/10.2165/00001495-19955020-00003 PMID:8521756

64. Sorgel F. Gender related distribution of quinolones. Eur J Clin Microbiol Infect Dis. 1991 (Special Issue); 1:189–90.

65. Robinson DP, Hall OJ, Nilles TL, Bream JH, Klein SL. 17β-estradiol protects females against influenza by recruiting neutrophils and increasing virus-specific CD8 T cell responses in the lungs. J Virol. 2014; 88:4711–20. https://doi.org/10.1128/JVI.02081-13 PMID:24522912

66. Piccini MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Sestili P, Mannucci P, Annnunziato F, Livi C. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol. 1995; 155:128–33. PMID:7541410

67. McKay Li, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev. 1999; 20:435–59. https://doi.org/10.1210/edrv.20.4.0375 PMID:1045354

68. Kawai K, Msmang G, Manji K, Villamor E, Bosch RJ, Hertzmark E, Fawzi WW. Sex differences in the effects of maternal vitamin supplements on mortality and morbidity among children born to HIV-infected women in Tanzania. Br J Nutr. 2010; 103:1784–91. https://doi.org/10.1017/S0007114509993862 PMID:20211040

69. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151:W65–94. https://doi.org/10.7326/0003-4819-151-4-200908180-00136 PMID:1962512

70. Savovíc J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, Higgins JP. Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014; 3:37. https://doi.org/10.1186/2046-4053-3-37 PMID:24731537

71. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557–60. https://doi.org/10.1136/bmj.327.7414.557 PMID:12958120

72. Sugita M, Kanamori M, Izuno T, Miyakawa M. Estimating a summarized odds ratio whilst eliminating publication bias in meta-analysis. Jpn J Clin Oncol. 1992; 22:354–58. PMID:1469797

73. Vandenburgroucke JP. Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ. 1998; 316:469–70. PMID:9492686
SUPPLEMENTARY MATERIALS

Supplementary Figures

Supplementary Figure 1. The research selection flowchart of this study.

Supplementary Figure 2. Risk of bias graph: judgements about each risk of bias item presented as percentages across all included studies.
Supplementary Figure 3. Risk of bias summary: judgements about each risk of bias item for each included study.
Supplementary Figure 4. The Begg’s funnel plot of OS for visual inspection.

Supplementary Figure 5. The Egger’s funnel plot of OS for visual inspection.
Supplementary Figure 6. The Begg’s funnel plot of PFS for visual inspection.

Supplementary Figure 7. The Egger’s funnel plot of PFS for visual inspection.
Supplementary Figure 8. Sensitivity analysis using OS as the endpoint of the study.

Supplementary Figure 9. Sensitivity analysis using PFS as the endpoint of the study.